Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis (UVE-FAS)

University Hospital of Bordeaux

Status: Completed

Conditions: Non-Infectious Active Uveitis

Treatments: Other: s-CD95-L

Study type: Observational

Funder types: Other

Identifiers

NCT04354909

CHUBX 2019/43

Details and patient eligibility

About

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies

Full description

Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group;
• Age ≥ 18 years;
• being affiliated to health insurance,
• willing to participate.

Exclusion criteria

• Pregnant or breastfeeding women,
• patient under legal protection measure ,
• poor understanding of the French language

Trial design

20 participants in 1 patient group

Biological samples

Description:

levels of s-CD95-L (ELISA test)

Treatment:

Other: s-CD95-L